Skip to main content
. 2021 Jul 9;14(9):893–904. doi: 10.1158/1940-6207.CAPR-20-0656

Table 1.

Baseline characteristics for 46 women randomized to placebo or ω-3 fatty acid supplementation arms.

Median (range) or N (%)
Total Placebo ω-3 fatty acids Comparison between arms
Variable N = 46 N = 23 N = 23 P a
A) Demographic and risk variables
Age, y 53 (40–67) 52 (40–63) 53 (42–67) 0.61
Tyrer-Cuzick 10-yr risk, % 8.4 (1.9–31.8) 9.0 (3.0–12.7) 7.6 (1.9–31.8) 0.38
Menopausal Peri 11 (24%) 6 (26%) 5 (22%) 1.00
 Post 35 (76%) 17 (74%) 18 (78%)
Genetic test Not tested 36 (78%) 19 (83%) 17 (74%) 0.15
 Wildtype 6 (13%) 1 (4%) 5 (22%)
 Del mutation 4 (9%) 3 (13%) 1 (4%)
Prior precancerous No 36 (78%) 18 (78%) 18 (78%) 1.00
 Yes 10 (22%) 5 (22%) 5 (22%)
On OC/HRT? No 29 (63%) 16 (70%) 13 (57%) 0.54
 Yes 17 (37%) 7 (30%) 10 (43%)
B) Anthropomorphic and body composition variables
Height, cm 165 (155–175) 163 (155–175) 165 (155–175) 0.15
Weight, kg 84.8 (69.2–115.6) 81.3 (69.2–111.2) 85.8 (75–115.6) 0.081
BMI, kg/m2 31.0 (27.9–42.4) 30.7 (27.9–39.8) 31.2 (27.9–42.4) 0.28
Waist circumference, cm 100 (80–120) 101 (80–115) 100 (84–120) 0.93
Body fat, percent 49 (37–55) 46 (37–55) 49 (42–53) 0.028a
FMI, kg/m2 14.3 (10.1–21.2) 13.5 (10.1–20.5) 14.7 (11.7–21.2) 0.11

aMann–Whitney nonparametric test, 2-sided. Similar lack of difference between randomized arms was observed if only the 42 women completing the 6-month intervention and evaluable for biomarkers were analyzed for baseline demographic and risk factors. Exceptions were the marginal statistical significance for body fat percent was lost (P = 0.078).